LGALS3BP: A Potential Prognostic Biomarker Influencing Antitumor Immunity in Triple-negative Breast Cancer

Anqi Hu; Shuaikang Pan; Yuan He; XueRu Wang; Dong Qian; Xiaoyang Li

doi:10.2174/0109298673367980250101053748

LGALS3BP: A Potential Prognostic Biomarker Influencing Antitumor Immunity in Triple-negative Breast Cancer

Curr Med Chem. 2025 Jan 20. doi: 10.2174/0109298673367980250101053748. Online ahead of print.

Authors

Anqi Hu^{1

2}, Shuaikang Pan², Yuan He¹, XueRu Wang^{1

2}, Dong Qian¹, Xiaoyang Li¹

Affiliations

¹ Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.
² School of Medical Oncology, Wan Nan Medical College, China.

PMID: 39838686
DOI: 10.2174/0109298673367980250101053748

Abstract

Objective: LGALS3BP exhibits differential expression in various types of tumors. This study aimed to analyze its potential diagnostic and prognostic value in Triple- negative Breast Cancer (TNBC).

Methods: We conducted a comprehensive analysis of LGALS3BP's differential expression and its association with patient survival outcomes using data from public databases. To further validate these findings, Immunohistochemistry (IHC) experiments were performed to confirm the differential expression of LGALS3BP protein in TNBC. Additionally, we also investigated the relationship among LGALS3BP, tumor immune infiltration, and drug sensitivity.

Results: Results indicated LGALS3BP to be significantly upregulated in TNBC, with its high expression correlating with improved survival outcomes. Furthermore, LGALS3BP expression correlated with immune cell infiltration. Notably, high LGALS3BP expression may confer a greater likelihood of benefiting from immunotherapy.

Conclusion: LGALS3BP may serve as a diagnostic and prognostic biomarker for TNBC.

Keywords: LGALS3BP; immune biomarker.; prognostic marker; triple-negative breast cancer.